• 沒有找到結果。

臨床微生物學- 細菌及黴菌學

N/A
N/A
Protected

Academic year: 2021

Share "臨床微生物學- 細菌及黴菌學"

Copied!
5
0
0

加載中.... (立即查看全文)

全文

(1)

~~

fi~

I:i!le

~.

~11

-~

~

.&.I.&.. ~

.ti

-•

Ifi

':::'

itt

~

~ ...

co

fa€~.

~

v

P<1t~

rn

rn

~

~~"

.

v

or-m!9I!.

-~

~~~

:ltttii

~

P-:I~~

~

~.

gJK

IB[~~

II

lMD

~

~

(2)

~, 'T ~*: ~I

liF.l:

lj ~~j ~tH :z ~t 1 ~~ tpL..1I ~q:s. ITt

:u

"'-' Il a;;1:t jf[/J fP ~jj\ lit 'l~ ~jJlj ~~i r... rc·§ ~~ rpt=.lt< ~fT. C, ~J!;:,: ix f.~ ~8- 2 1-1 .',,,,. o/lij 1-2

li

~x.~ 1~~~* ~JlJJ

JlHilfi.Jt

27 ( #JE~B ' 5~f,Bffx ) 2-1

-{jHiW

( General Characteristics ) 32

2-2 ~~ ~:t ~ ( Clinical Significance) 33

2-3

±g

*"~.;f,ti.&Jt

1i.7i

~ ( Cultural Characteristics & ldentification ) 44

r_...

(!}B~It)

3-1 - ~

H

.

W

(General Characteristics) 52 3-2 ~iJt.:t,n ( Clinical Significance) 54

3-3

:Ig-'l!t+'ti.&.$tR7JA:

( Cultural Characteristics & Identification ) 54

3-4 ~

W

f,iJ

~

'ti

tt~ ( Antimicrobial Susceptibility Testing) 56

3-5 ~

Wi

/

5tt

IT.:iN ~

( Prevention / Epidemiology ) 58

3-6 ~ fVlJ

li1f'1..

( Case Study) 59

(~B~It)

4-1 -

A9:

,tt

~ ( General Characteristics ) 62

4-2 ~.Th

'*

~i ( Clinical Significance ) 62

4-3 ±15

*"

#-

,tt

Jjz ~;t

1i

A;; ( Cultural Characteristics & Identification) 64

4-4 ~~m ~~,titt~t (Antimicrobial Susceptibility Testing) 66 4-5 "ffl

!lfl

/

5*

rr

~

*

( Prevention / Epidemiology ) 67

4-6

m

i7~

ffl

~ (Case Study ) 67

(~~m)

5-1 -

hHi

J

(General Characteristics ) 72 5-2 ~ t*.~~ ( Clinical Significance ) 73

5-3

±g.:i-4f'tilHIJt7i:7i

( Cultural Characteristics & Identification ) 74

5-4 ~#J~~'li~~ ( Antimicrobial Susceptibility Testing ) 78

(3)

x xi " ~ 5-6 ~ i9~

Wf

~ ( Case Study ) 81

(

~~tf )

6-1

-A9:,ti}t

( General Characteristics ) 86 6-2

1m *;t,

i; (Clinical Significance ) 87

6-3

±-g:,*#

·ti:&.~;z:t-)! (Cultural Characteristics & Identification) 88

6-4 ~4fJJ ~~

U

.

~~~ (Antimicrobial Susceptibility Testing ) 89

~*

6-5 ffJ pjj/ if[

iT

~ ~ ( Prevention / Epidemiology ) 90

~

t+JU

"'if! 6-6

ffl

i9'J ~11:. ( Case Study ) 91

~ L

,

(~tLiE

)

~~: 7-1 -

M

.

't!

';! ( General Characteristics ) 96

7-2 liJ;lildi~ ( Clinical Significance) 97

~ (~J..1iE )

10-1

-

~9:·tt

1t

(General Characteristics ) 122

10-2 ~£

*;t,

i

( Clinical Significance) 123

10-3

±g

'~!f+

·ti.&.

~;tff)! (Cultural Characteristics & 1dentification) 127

10-4

-

#J M

~·tt~,~ ( Antimicrobial Susceptibility Testing) 138 10-5

fflilt

/

1if.1i

#ii

~ ( Prevention / Epidemiology ) 144

10-6 ~

19

IJ ~ ~ ( Case Study ) 146

( ;'i /J\5$ )

11-1

-

~~·ti

J

( General Characteristics ) 150

11-2 ~~

*

~

it

(Clinical Significance) 151

11-3

tg*"ij;f

·

ti.&Jttt7J

5l-

(Cultural Characteristics & fdentification ) 162

11 -4 ~

#J

~

'Jt

'ti

tt.lYk

( Antimicrobial Susceptibility Testing ) 171

11-5

ffi

~jj /

.;tt

IT

~ ~ ( Prevention / Epidemiology ) 171

~~l 98

7-3

±

g

*-

4~'tibHfi ~j]

Ai:

( Cultural Characteristics & Identification)

f

l

,

!

'-'- 11 -6 mi9~

¥f

~ ( Case Study) 171

7-4 ~ ~m ~~

·ti

~~ ( Antirillcrobial Susceptibility Testing ) 102

~1

n 7-5

ffi

WI

/

$t

rr

~ ~ ( Prevention / Epidemiology ) 102

.

-'.

~~~ 7-6 ~i9IJtiJ!-JL ( Case Study ) 102

12-1 -

A9:

·

ti

jt ( General Characteristics) 176

~q:E

(

~l-:LlE

)

12-2

1m

*;t:lt

(Clinical Significance) 178

12-3 :l-tH~*f'ti.&.~;t7f)i (Cultural Characteristics & Identification) 179

...., 8-1 -

h9:

·ti

jf[ (General Characteristics ) 106

12-4 ~w~~·ti~~ (Antimicrobial Susceptibility Testing) 187

5::::1i 8-2 ~~*jt;ft (Clinical Significance) 106

"'/ ) 12-5

ffi

P.t

/

5JiE fT~ ~ ( Prevention / Epidemiology ) 188

8-3 :l:fH~·tHi:&' ~Jt

7J

*

(Cultural Characteristics & Identification ) 107

12-6 ~i9n~D'E (Case Study ) 189

8-4 ~

#J ~

1t'riv\'~ ( Antimicrobial Susceptibility Testing ) 109

~

/-8-5

ffl

~n

/

5)it

if

~!f. ( Prevention / Epidemiology ) 110

~;~ 8-6

ffJ

i91

~~ (Case Study ) 111

n ( ~~t~ )

J i t

13-1

- AlHi 91

( General Characteristics ) 194

mifr

9-1 -

AHi

it

(General Characteristics ) 114 13-2 ~.lj;

'*

:t,n

( Clinical Significance ) 197

B~i 13-3

±g

*~·tilH.l~:ff

Ai:

(Cultural Characteristics & ldenl'ification ) 199

( ~l-ilE

)

9-2 ~~ ~

i:.i

(Clinical Significance) 115

... ~ 116 13-4 ~~

(TI-ealment ) 202

r:p'-f 9-3

±

g

*4~,tilk

it

J:t7J

*

(Cultural Characteristics & Identification)

I

I

.

9-4 •

#J

M-

~.t!$\~ ( Antimicrobial Susceptibi lity Testing ) 118 13-5 tri P1i / 5fif,

i

T

~:$ ( Prevention / Epidemiology ) 203

~~

~f~ 9-5 fff!I;Q / S:nf.

rr

1rtJ!:Q:. ( Prevention / Epidemiology ) 11 8 13-6

WJ

ifl] \i}f ~ ( Case Study ) 204

ff!~f1 9-6 ~-WI] :{iJD'E ( Case Study ) 120

't:;t

(4)

~ ~~ U :J CiJ3

5

R

5N

5

N

:

5N

l

t+l1J.. ~~H Ii 7 ± / J f1~ 1: ~/. ~j~ n

mj

fl

I B~~ I Inl :P::-I ~~

""

~¥. I xii (f1iJii~

)

14-1 - ~

,tt

~ ( General Characteristics) 210 14-2 ~~.DR!: ~ (Clinical Significance ) 216

14-3

115

fi

¥t ,tt&

~.it jj)!: ( Cultural Characteristics & Identification ) 22 1

L4-4 ~#J ~ j:,ti~. $ ( Antimicrobial Susceptibility Testing ) 23 3

14-5

ffi

1l1J

/

)tE

iT

~ ~ ( Prevention I Epidemiology ) 235 14-6 ~ ~IJ

iiJf

Jt

(Case Study ) 236

(OO,filt

)

15­] -

A(( '

r!

J

(General Characteristics ) 242

15-2 ~~~

'*

jt~ ( Clinical Significance ) 242

15-3 ±~~4-Hi'& ~.it7f

A:

( Cultural Characteristics & Identification ) 244

15-4 ~~m ~ ~·Iit~. ~ ( Antimicrobial Susceptibility Testing) 247

15-5

ffI

flfr

/

5JiE

h

m

~ ( Prevention / Epidemiology ) 248

15-6 ;,'[f.J

19':

li1T ~ ( Case Study ) 248

(~jt&~)

16-1

-ml:'tl

~ ( General Characteristics ) 252

16-2 ~:11

'*

1t

~ (Clinical Significance ) 253

16-3 ±gltf~;lftl:.:&iiJt7f5! ( Cultural Characteristics & Identification ) 254

16-4 ~

4m

fo!& ~

·thi\.f)t

( Antimicrobial Susceptibility Testing ) 261

16-5

Ai

Xf

/

ffi

f!jj ( Treatment/Prevenrion) 261

16-6 ~ i9~ lfJt-~ ( Case Study) 262

( ~3t~~ )

17­1 -~~,t1 Jlr (General Characteristics ) 266 17-2 ~ ~:@:~ (Clinical Significance ) 266

17-3 115

fi-lt·1'i

.

&Jt

ltjj5! ( Cultural Characteristics & Identification ) 267

17-4 ~

#J

~~ ~,t1-~~ (Antimicrobial Susceptibility Testing) 268

17-5

nHn

( Prevention ) 269

17-6 ~ i9~!iJf ~ ( Case study) 269

(~3t!w.

)

18-1

-M:'ti

j.r ( General Characteristics) 274

II

\8-2 18-3 18-4 18-5 18-6 19-1 19-2 19-3 19-4 19-5 19-6 20-1 20-2 20-3 20-4 20-5 20-6 20-7 21-1 21-2 21-3 21-4 21-5 22-1 22-2 22-3 xiii

~I7R

'.t-il

(Clinical Significance ) 274

}ff

it

i~ ·~i.&.~Jt7J$. ( Cultural Characteristics & Identification) 274

li4m

1.'$ ~·ti~~ ( Antimicrobial Susceptibility Testing ) 275

fff

IW

( Prevention ) 275

~ 17~

1i}f-:JE

(Case Study ) 275

L

(~3t~)

- ~Q:

·ri

~ ( General Characteristics ) 280

~J~ ~;@: ~ ( Clinical Significance ) 280

*~"i;f·t.i&~.ltjj ~ (Cultural Characteristics & Identiiication ) 281

~#1

.tJ

~

H

~~i ( Antimicrobial Susceptibility Testing ) 282

ffi

IYJ (Prevention ) 283

m

f91j"~f-

Jt

(Case Study ) 283

(

5Nlt!~

,

~fa~Bi

)

-M::·ti

~ ( General Characteristics ) 288

Gra

fiR:t

~

(

Clinical Significance ) 290

J~w4~,ti&*.lt/J)! ( Cu ltural Characteri stics & Identification ) 297

m

fft

ill

~#; ( Antifungal Agents) 301

jfJffi

/

ffi

IYJ

/

:IJfE

ft

~

*

( TreatmentlPrevention /Epidemiology ) 302

~

E

ff.~

'f.

tt

J..1j ( Techniques in Mycology Lab ) 303

~

19

1]

\iff

~ ( Case Study ) 305

1 '''r

.. f'" -I _ _ ~ (~:&~)

-

MUiJf

( General Characteristics ) 308

fri..i

"t

.:t.

i"l=

ffJ

~ ~ ( Mechanisms of Antibiotic Resistance ) 308

fri:

~·tt

:::'

At...

( Mechanisms of Antibiotic Resistance ) 313

~

4m

%

~

,tt

~~ ( Antimicrobial Susceptibility Test ) 316

~

iqu !iJf

~ (Case Study ) 328

_.

___-

_

(

fiI~~

)

1ltr~ 332

r7t

I*J

I,~!d~~.

99

jJ\. ~.&. ~~ ~ 333

(5)

_________________

__

_

________________

_

xi\'

22-4

il'

Hi

~ ~

tal,

~1l[)}l 335

22-5

ir.d~

.

1J¥d:

.

#J~'

~

:tit

I1t

pt]

~

~

~

:jQ

rjf!t

jQ

±-

1:f

~f

~~

4J

a.

":'r-J -r­

~,*fy&

~4~*~~ifB

tJ

1lt

*

r----..---,

22-6 f#-jHtl'f.J~klJL ' q~.~1t~1t 337

22-7 ~1~,jli}f~ ( Case Study ) 339

~

o+l j!f1 i~-

:

1:.tm~~~

i"FtI

343

tt

m.~:~~.~#J*$~M~a~~~~. 3M

'fIl

'j m.~ : ~~~*~.&~~~a 3~

M

pfH~ [9 :

lin.

:I{')~AIT

i:

71<.

lit-ItiJN

364

11 ~IHlll.

:

1mlrfi

7t!M

fi1j 11'- 367 *)C%,~1 373 ~ .:J:-'

tf

)c

%'

iJl

386 ~~ J.~ ~~ tI1 ~~ ~u ~q: ±/ c /j IJ../ ]fi, ~ m:~ 'i1 U

mi,

E~i

.,

t;J ~1; qJn ~ff ~ 33 7

I

~~EI~

I

*'~

.

I

I

I

I

I

___

L

_®f'H~

~2js:M~

~ttf;ItJ

~'*M~~~~m~~

~'*~U®~~W~~

~ruJ.m~~~~5lT~~fJ{f(q ~m_iil'l',JfIl~ 0 ~2js:frJ!i~~fJ{fijq o ~'*1l'fi~~tAA~m~%H~ 0 ~'*~ff1(j{]qt~~~;£ffi

lfilm~J~¥~Ii@~?tT~I:J~:fJiffq 0

~'*~~~rr~~l¥Jd1~ o 'tf~*2(~ o ~'*~~~8'_JJTh~

I

11gn~~?t:

!fIf!iEr~~2(~~x~mUlUttm5E

~1m2(~~

~&~

-m:

I

I

~~2(~~~~=~

~

~2(~~~m~

~

I

I

~~~*~ ~

t

參考文獻

相關文件

(一)選用 TKS1-1 以及 WG6-14 兩種不同類型的枯草桿菌,了解其特性. 圖一、PSA 培養基中畫菌圖(TKS1-1)

自抗生素發現至現在這 50 年稱為所謂的傳統抗生素時期(classical antibiotic

一、對抗生素Meropenem Trihydrate 具抗藥性(R 菌)和不具抗藥性(S 菌)的 Acinetobacter baumannii 菌在蛋白質電泳實驗中,比較蛋白質表現的差異。(文中所用代號: 「R

狼尾草(Pennisetum purpureum)為本國主要之青芻料之一,是以兩個高產狼尾草 A146 與

(3) Day 6, 04Nov2015, subject 5120001:病人轉用 口服抗生素若為 pathogen based therapy,依計 畫要求應先提供細菌培養報告並取得medical

使用完畢,開啟 Turbomass 軟體中之 Tune Page,點選 Shutdown 檔案,Mass 會自動 將 Source 及 Transfer line

使金屬離子均勻分散在纖維中而具有抗菌作用。抗菌

而在後續甲烷化反應試驗方面,以前段經厭氧醱酵產氫後之出流水為進流基 質。在厭氧光合產氫微生物方面,以光合作用產氫細菌中產氫能力最好的菌株 Rhodopseudomonas palustris